The Safety and Efficacy of Good Feeling Power® for IBD Patients

An Open-Label Pilot Study to Determine Safety and Efficacy of Good Feeling Power® (a Dietary Supplement) in Patients With Either Ulcerative Colitis or Colonic/Ileal Crohn's Disease

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07766733

Enrollment

Registered

2026-08-14

Start date

2023-11-06

Completion date

2025-06-20

Last updated

2026-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease (CD), Ulcerative Colitis (UC)

Brief summary

This open-label pilot study aims to evaluate the safety and efficacy of the dietary supplement Good Feeling Power® for patients with mild-to-moderate ulcerative colitis and colonic/ileal Crohn's disease.

Interventions

DIETARY_SUPPLEMENTGood Feeling Power®

The dietary supplement Good Feeling Power®, isolated from the fruiting bodies of the tree mushroom (tinder fungus, lat. Fomes fomentarius), was administered orally as a drink.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 64 Years

Healthy volunteers

Inclusion criteria

* Adults aged 18 - 64 * BMI 18.5 - 32.0 kg/m² * Mild-to-moderate UC or colonic/ileal CD * At least one prior episode of active disease

Exclusion criteria

* Extensive colonic resection or subtotal or total colectomy * Currently required or anticipated surgical intervention during the study * Any prior exposure to natalizumab, efalizumab, or rituximab * History or evidence of colonic mucosal dysplasia * Female patients who are lactating or have a positive pregnancy test * Any unstable or uncontrolled medical disorder that, in the opinion of the investigator, would confound the study results or compromise patient safety.

Design outcomes

Primary

Measure	Time frame	Description
The effect of Good Feeling Power® on gastrointestinal symptoms, biochemical biomarkers and endoscopic parameters	From baseline to Day180	The primary outcomes are the changes in gastrointestinal symptoms (Simple Clinical Colitis Activity Index for ulcerative colitis (UC) patients and the Harvey-Bradshaw Index for Crohn's disease (CD) patients), biochemical biomarkers in feces (calprotectin, immunoglobulin A, hemoglobin), and endoscopic parameters (Mayo Endoscopic Score).

Secondary

Measure	Time frame	Description
Safety of Good Feeling Power® for patients with mild-to-moderate UC or CD	From baseline to Day180	The secondary outcomes are the safety of the tested product, as monitored by vital signs, ECG, physical condition, blood parameters (hematology, clinical chemistry, coagulation, and inflammation), urine analysis, and the absence of the product-related adverse effects.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 15, 2026